Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy

Conditions:Lymphoma, Lymphoma
Therapuetic Areas:Oncology
Age Range:18 - Any
Start Date:December 27, 2017
End Date:November 2022
Contact:Carolyn Andrews, RN

Use our guide to learn which trials are right for you!

Phase II Study of Venetoclax (ABT-199/GDC-0199) in Combination With Obinutuzumab and Bendamustine in Patients With High Tumor Burden Follicular Lymphoma as Front Line Therapy

Patients with high tumor burden, low grade follicular lymphoma that has never been treated,
will receive venetoclax in combination with obinutuzumab and bendamustine.

Venetoclax is an oral Bcl-2 family protein inhibitor. It targets the B-cell lymphoma 2
(BCL-2) protein, which supports cancer cell growth and is overexpressed in many patients with
follicular lymphoma. Venetoclax may help to slow down the growth of cancer or may cause
cancer cells to die.

The purpose of this study is to see whether adding venetoclax to obinutuzumab and
bendamustine improves the response (the tumor shrinks or disappears) in patients with
follicular lymphoma.

As of 9/5/2018, a higher than expected incidence of tumor lysis syndrome (TLS) was
experienced among patients receiving venetoclax, obinutuzumab and bendamustine on Cycle 1,
Day 1 of treatment. TLS is caused by the fast breakdown of cancer cells. These patients
developed an increase in some of their blood tests (uric acid, phosphorus, potassium and/or
creatinine). They received a medication called rasburicase and continued with treatment. It
is unclear if the TLS was due to the venetoclax or the standard treatment of obinutuzumab and
bendamustine. For the remaining patients, venetoclax will start on Cycle 2, Day 1 (previously
Cycle 1, Day 1).

Follicular lymphoma (FL) is the most common low grade lymphoma comprising 70% of low-grade
non-Hodgkin's lymphoma (NHL) and 22% of all cases of NHL. The survival rates for patients
with indolent NHL remained unchanged from the 1950s through the early 1990s, but recent
evidence suggests that outcomes continue to improve. High-risk patients with FL, defined as
having advanced stage and high tumor burden have significantly shorter progression free
survival despite significant advances.

This is an open-label phase II study of venetoclax in combination with obinutuzumab and
bendamustine. Patients will receive induction therapy with obinutuzumab and bendamustine for
six cycles (1 cycle = 28 days). Venetoclax will start with 2nd cycle of induction therapy
(previously started with cycle 1). There will be a formal, detailed toxicity evaluation after
21 patients complete 3 cycles of treatment.

Patients who achieve partial response or stable disease will receive therapy with
obinutuzumab every 2 months for 12 cycles and venetoclax every month for 24 cycles. Patients
who achieve a complete response will receive obinutuzumab every 2 months for 12 cycles.
Patients with progressive disease will not continue onto the maintenance arm.

Tumor assessments will be performed approximately every 12 weeks during induction and every 6
months during maintenance therapy.

Mandatory pre-treatment tumor tissue sample (i.e., obtained during a previous procedure or
biopsy) will be required for research (if sufficient tissue is available). Optional tumor
biopsy samples obtained during treatment or post-treatment will also be requested for

- Patient must have a histologically confirmed (biopsy-proven) diagnosis of follicular
B-cell non-Hodgkin lymphoma (WHO classification: follicular center grades 1, 2, and 3a
[3b patients are not eligible]), with no evidence of transformation to large cell

- Patient must meet criteria for High Tumor Burden (higher risk) as defined by either
the Groupe D'Etude des Lymphomes Follicularies (GELF) criteria [at least one
criterion] OR the follicular lymphoma international prognostic index (FLIPI) [score of
3, 4, or 5].

- Patient must have Stage II, III or IV disease.

- Baseline measurements and evaluations (PET/ CT) must be obtained within 10 weeks of
randomization to the study. Patient must have at least one objective measurable
disease parameter.

- Age ≥ 18 years.

- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.

- Ability to understand and willingness to sign Institutional Review Board
(IRB)-approved informed consent.

- Willing to provide mandatory tissue samples (if sufficient tissue available) for
research purposes.

- Adequate organ function as measured by the following criteria:

- Absolute Neutrophil Count (ANC) ≥ 1000/mm³

- Hemoglobin ≥ 8 g/dL

- Platelets ˃75,000/mm³

- Creatinine clearance ≥ 50 mL/min, calculated with the use of 24-hour creatinine
clearance or by Cockcroft-Gault formula

- Total Bilirubin ≤ 1.5x Upper Limit of Normal (ULN) or ≤ 3x ULN for patients with
documented Gilbert's syndrome

- Aspartate aminotransferase (AST)/ alanine aminotransferase (ALT) ≤ 2.5x ULN

- Alkaline Phosphatase <5x ULN

- All females of childbearing potential (not surgically sterilized and between menarche
and 1 year post menopause) must have a blood or urine test to rule out pregnancy
within 2 weeks prior to registration.

- Women must not be pregnant or breastfeeding.

- Patient must have had no prior chemotherapy, radiotherapy or immunotherapy for
lymphoma. For purposes of this trial, prednisone or other corticosteroids used for
non-lymphomatous conditions will not be considered as prior chemotherapy. In addition,
a prior/recent short course (<2 weeks) of steroids for symptom relief of
lymphoma-related symptoms will not make a patient ineligible.

- Patient must have no recent history of malignancy except for adequately treated basal
cell or squamous cell skin cancer, Stage I melanoma of the skin, or in situ cervical
cancer. Individuals in documented remission without treatment for ≥ 2 years prior to
enrollment may be included at the discretion of the investigator.

- Patient must have no active, uncontrolled infections.

- Patients must be tested for hepatitis B virus (HBV), hepatitis B surface antigen
(HBsAg+) and hepatitis C (HCV) antibody within 6 weeks of registration. Patients who
are chronic carriers of HBV with positive HBsAg+ and positive HCV serology are
excluded, as chemotherapy and B-cell depleting therapy have been associated with virus
reactivation and fulminant hepatitis. NOTE: Patients with a past or resolved HBV
infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence
of HBsAg) may be included if HBV DNA is undetectable. If enrolled, patients must be
willing to undergo monthly HBV DNA testing. Patients with positive HCV antibody must
be negative for HCV by polymerase chain reaction (PCR) to be eligible for study

- HIV positive patients are not excluded, but to enroll, must meet all of the below

- HIV is sensitive to antiretroviral therapy.

- Must be willing to take effective antiretroviral therapy if indicated.

- No history of CD4 prior to or at the time of lymphoma diagnosis <300 cells/mm³.

- No history of AIDS-defining conditions.

- If on antiretroviral therapy, must not be taking zidovudine or stavudine.

- Must be willing to take prophylaxis for Pneumocystis jiroveci pneumonia during
therapy and until at least 2 months following the completion of therapy or until
the CD4 cells recover to over 250 cells/mm³, whichever occurs later.

- Evidence of significant, uncontrolled concomitant diseases that could affect
compliance with the protocol or interpretation of results or that could increase risk
to the patient.

- No major surgery within 2 weeks prior to cycle 1, other than for diagnosis.

- A condition that precludes oral route of administration (venetoclax).

- No known allergies to both xanthine oxidase inhibitors and rasburicase.

- Patient must not require the use of warfarin (because of potential drug-drug
interactions that may potentially increase the exposure of warfarin). Blood thinners
of other classes are permitted.

- Patient may not receive the following agents within 7 days prior to the first dose of

- Strong and moderate CYP3A inhibitors

- Strong and moderate CYP3A inducers

- Consumed grapefruit, grapefruit products, Seville oranges (including marmalade
containing Seville oranges), or star fruit within 3 days prior to the first dose
of venetoclax.

- Patient must not have serious medical or psychiatric illness likely to interfere with
participation in this clinical study.
We found this trial at
1365 Clifton Rd NE
Atlanta, Georgia 30322
(404) 778-1900
Principal Investigator: Jonathon Cohen, MD
Phone: 404-778-2214
Winship Cancer Institute at Emory University Winship Cancer Institute of Emory University is Georgia
Atlanta, GA
Click here to add this to my saved trials
2220 Pierce Ave
Nashville, Tennessee 37232
Principal Investigator: Nishitha Reddy, MD
Phone: 615-343-1467
Vanderbilt-Ingram Cancer Center The Vanderbilt-Ingram Cancer Center, located in Nashville, Tenn., brings together the clinical...
Nashville, TN
Click here to add this to my saved trials
Baltimore, Maryland 21231
Principal Investigator: Nina Wagner-Johnson, MD
Phone: 410-614-7834
Baltimore, MD
Click here to add this to my saved trials
Charlottesville, Virginia 22903
(434) 924-0311
Principal Investigator: Craig Portell, MD
Phone: 434-297-7783
University of Virginia The University of Virginia is distinctive among institutions of higher education. Founded...
Charlottesville, VA
Click here to add this to my saved trials
1900 South Avenue
La Crosse, Wisconsin 54601
Principal Investigator: Kurt Oetell, MD
Phone: 608-775-2837
La Crosse, WI
Click here to add this to my saved trials
Madison, Wisconsin 53792
(608) 263-2400
Principal Investigator: Christopher Fletcher, MD
Phone: 608-262-9818
University of Wisconsin In achievement and prestige, the University of Wisconsin–Madison has long been recognized...
Madison, WI
Click here to add this to my saved trials
New Brunswick, New Jersey 08901
Principal Investigator: Kevin David, MD
Phone: 732-235-6008
New Brunswick, NJ
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19111
Principal Investigator: Nadia Khan, MD
Phone: 215-214-3173
Philadelphia, PA
Click here to add this to my saved trials
Rochester, Minnesota 55905
Principal Investigator: Grzegorz Nowakowski, MD
Phone: 507-226-9686
Rochester, MN
Click here to add this to my saved trials
660 S Euclid Ave
Saint Louis, Missouri 63110
(314) 362-5000
Principal Investigator: Brad Kahl, MD
Phone: 314-362-3257
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
Saint Louis, MO
Click here to add this to my saved trials